Hypoglycemia Pipeline Review, H1 2019 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Hypoglycemia
– Pipeline Review, H1 2019” drug pipelines has been added to ResearchAndMarkets.com’s
offering.

This latest pipeline guide Hypoglycemia – Pipeline Review, H1 2019,
provides comprehensive information on the therapeutics under development
for Hypoglycemia (Metabolic Disorders), complete with analysis by stage
of development, drug target, mechanism of action (MoA), route of
administration (RoA) and molecule type. The guide covers the descriptive
pharmacological action of the therapeutics, its complete research and
development history and latest news and press releases.

The Hypoglycemia (Metabolic Disorders) pipeline guide also reviews of
key players involved in therapeutic development for Hypoglycemia and
features dormant and discontinued projects. The guide covers
therapeutics under Development by Companies /Universities /Institutes,
the molecules developed by Companies in Pre-Registration, Phase III,
Phase II, Phase I, Preclinical and Unknown stages are 2, 1, 2, 5, 4 and
2 respectively.

The Hypoglycemia (Metabolic Disorders) pipeline guide helps in
identifying and tracking emerging players in the market and their
portfolios, enhances decision-making capabilities and helps to create
effective counter strategies to gain competitive advantage. The guide is
built using data and information sourced from the researcher’s
proprietary databases, company/university websites, clinical trial
registries, conferences, SEC filings, investor presentations and
featured press releases from company/university sites and
industry-specific third party sources. Additionally, various dynamic
tracking processes ensure that the most recent developments are captured
on a real time basis.

Scope

• The pipeline guide provides a snapshot of the global therapeutic
  landscape of Hypoglycemia (Metabolic Disorders).
• The pipeline guide reviews pipeline therapeutics for Hypoglycemia
  (Metabolic Disorders) by companies and universities/research
  institutes based on information derived from company and
  industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of
  development ranging from pre-registration till discovery and
  undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline
  products which comprise, product description, descriptive licensing
  and collaboration details, R&D brief, MoA & other developmental
  activities.
• The pipeline guide reviews key companies involved in Hypoglycemia
  (Metabolic Disorders) therapeutics and enlists all their major and
  minor projects.
• The pipeline guide evaluates Hypoglycemia (Metabolic Disorders)
  therapeutics based on mechanism of action (MoA), drug target, route of
  administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued
  pipeline projects.
• The pipeline guide reviews latest news related to pipeline
  therapeutics for Hypoglycemia (Metabolic Disorders)

Reasons to buy

• Procure strategically important competitor information, analysis, and
  insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio
  and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under
  development for Hypoglycemia (Metabolic Disorders).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of
  leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players
  and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding
  Hypoglycemia (Metabolic Disorders) pipeline depth and focus of
  Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by
  identifying prospective partners with the most attractive projects to
  enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects
  and understand from the know-how what drove them from pipeline.

Companies Mentioned

• Adocia SAS
• AMAG Pharmaceuticals Inc
• Arecor Ltd
• Eiger BioPharmaceuticals Inc
• Eli Lilly and Co
• LATITUDE Pharmaceuticals Inc
• Novartis AG
• Rezolute Inc
• Sosei Heptares
• Therakind Ltd
• USV Pvt Ltd
• XERIS Pharmaceuticals Inc
• Zealand Pharma AS
• Zucara Therapeutics Inc

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/mopseu

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international
market research reports and market data. We provide you with the latest
data on international and regional markets, key industries, the top
companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Gastrointestinal
Drugs, Endocrine
and Metabolic Disorders Drugs